Loading...
•
Jun 30, 2020
Lineage Q2 2020 Earnings Report
Reported financial results for the second quarter of 2020 and provided a business update.
Key Takeaways
Lineage Cell Therapeutics reported positive milestones across its cell therapy pipeline, including retinal tissue restoration in a dry AMD patient. The company is advancing its dendritic cell vaccine program and making manufacturing improvements for its OPC1 program.
Reported the first known finding of retinal tissue restoration in a dry AMD patient, with a 25% reduction in the area of geographic atrophy.
Exercised an option with Cancer Research UK to assume responsibility for advancing the dendritic cell vaccine program.
Made significant progress developing and implementing manufacturing improvements for the OPC1 program to treat spinal cord injuries.
Cash, cash equivalents, and marketable securities totaled $20.3 million as of June 30, 2020.
Forward Guidance
Lineage has the following plans and objectives for the second half of 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...